PatientsVille.com Logo

NASOPHARYNGITIS and Prozac

PatientsVille

NASOPHARYNGITIS Symptoms and Causes

We are sorry, but no medical information on this topic currently exists in our database. Our articles are updated often, please revisit soon.

Check out the latest treatments for NASOPHARYNGITIS

NASOPHARYNGITIS treatment research studies

Prozac clinical trials, surveys and public health registries


Find Drug Side Effect reports



Prozac Side Effects

Depression (189)
Anxiety (147)
Suicidal Ideation (139)
Feeling Abnormal (138)
Suicide Attempt (118)
Nausea (117)
Headache (117)
Completed Suicide (116)
Vomiting (110)
Pain (109)
Insomnia (109)
Aggression (107)
Fall (104)
Dyspnoea (99)
Fatigue (96)
Convulsion (96)
Agitation (95)
Tremor (90)
Abnormal Behaviour (90)
Confusional State (87)
Dizziness (46)
Loss Of Consciousness (45)
Condition Aggravated (45)
Diarrhoea (44)
Asthenia (43)
Somnolence (43)
Overdose (42)
Anger (42)
Homicide (41)
Death (39)
Arthralgia (39)
Malaise (37)
Irritability (35)
Off Label Use (35)
Mania (35)
Weight Decreased (34)
Serotonin Syndrome (34)
Weight Increased (33)
Chest Pain (32)
Hypertension (32)
Crying (32)
Pain In Extremity (31)
Amnesia (31)
Anaemia (29)
Rash (29)
Cerebrovascular Accident (29)
Syncope (27)
Hyperhidrosis (26)
Pruritus (26)
Hyponatraemia (26)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

NASOPHARYNGITIS Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting Fluoxetine Prevention Trial
Condition: Cognitive Dysfunction
Interventions: Drug: Fluoxetine;   Drug: Placebo
Outcome Measures: Change from baseline in regional cerebral metabolism;   Durability of the protective effect of fluoxetine;   Change from baseline in neuropsychological (cognitive, functional) test results;   Correlation between cognitive functioning and cerebral metabolism by correlating neuropsychological testing results with PET imaging;   Correlation between inflammatory cytokines and cerebral metabolism by correlating blood cytokine marker levels with PET imaging
2 Not yet recruiting "Evaluation by Transcranial Magnetic Stimulation of the Benefit of Fluoxetine on Motor Recovery After Stroke"
Condition: Cerebral Infarction
Interventions: Drug: Fluoxetine;   Drug: Placebo of fluoxetine
Outcome Measures: Slope of the curve of recruitment of the PEMs;   Slope of recruitment of the PEMs;   Index finger force control in paretic hand under time-course of treatment of Fluoxetine;   in index finger force control in non-paretic hand under time-course of treatment of Fluoxetine
3 Unknown  Predictors of Treatment Response to Fluoxetine in PTSD Following a Recent History of War Zone Stress Exposure
Condition: Posttraumatic Stress Disorder, Combat-related
Interventions: Drug: Fluoxetine;   Drug: Placebo
Outcome Measures: Clinician Administered PTSD Scale;   PTSD Symptom Checklist
4 Recruiting A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression
Condition: Treatment Resistant Depression
Interventions: Drug: Olanzapine;   Drug: Fluoxetine;   Drug: Placebo
Outcome Measures: Mean Change from Baseline to 8 Week Endpoint in Montgomery-Äsberg Depression Rating Scale (MADRS);   Mean Change from Baseline to 8 Week Endpoint in Clinical Global Impressions-Severity of Depression (CGI-S) Scale;   Mean Change from Baseline to 8 Week Endpoint in the Simpson-Angus Scale (SAS);   Mean Change from Baseline to 8 Week Endpoint in the Short-Form 36 Health Survey (SF-36);   Mean Change from Baseline to 8 Week Endpoint in the Sheehan Disability Scale (SDS);   Percentage of Participants who Achieve a Response Based on a ≥50% Reduction from Baseline in MADRS Total Score;   Percentage of Participants who Achieve Remission Based on MADRS Total Score ≤10 at 8 Weeks;   Mean Change from Baseline to 8 Week Endpoint in the Barnes Akathisia Scale (BAS);   Mean Change from Baseline to 8 Week Endpoint in the Abnormal Involuntary Movement Scale (AIMS)
5 Recruiting Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder
Condition: Major Depressive Disorder
Interventions: Drug: Fluoxetine + Valsartan;   Drug: Fluoxetine + Placebo
Outcome Measures: Hamilton Depression Rating Scale (HDRS);   fasting plasma glucose;   fasting serum insulin;   C-reactive Protein, and IL-6
6 Recruiting Effectiveness Study to Compare Venlafaxine With Fluoxetine in the Treatment of Postmenopausal Women With Major Depression
Condition: Major Depression
Intervention: Drug: venlafaxine,fluoxetine
Outcome Measures: change of 24-item Hamilton Rating Scale for Depression total score;   the mean change of HAMD-24 subscale score in items 10, 11, 12, 13 (anxiety and somatizations) at endpoint
7 Recruiting Fluoxetine for Motor, Aphasia, and Neglect Recovery After Ischemic Stroke
Condition: Stroke
Interventions: Drug: fluoxetine;   Drug: placebo
Outcome Measures: Fugl-Meyer Motor Scale (FMMS);   Western Aphasia Battery;   Behavioral Inattention Test (BIT);   Functional Independence Measure
8 Recruiting Fluoxetine for Motor Recovery After Acute Intracerebral Hemorrhage
Conditions: Intracerebral Hemorrhage;   Motor Impairment
Interventions: Drug: Fluoxetine;   Drug: Placebo
Outcome Measures: Fugl Meyer Motor Scale score;   Barthel Index;   modified Rankin Scale;   NIH Stroke Scale
9 Unknown  Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Fluoxetine
Outcome Measures: The primary endpoint will be change in pulmonary vascular resistance (PVR) measured by right heart catheterization after three months of therapy.;   Efficacy, Safety and tolerability endpoints will include change between baseline and three month QIDS-SR depression scale, systolic and diastolic blood pressure (systemic) and tabulation of adverse events
10 Recruiting Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM)
Conditions: Type 1 Diabetes;   Hypoglycemia Associated Autonomic Failure
Interventions: Drug: Fluoxetine;   Drug: Placebo control
Outcome Measure: Change in Catecholamines
11 Unknown  Pharmacogenomics Studies of Antidepressants
Conditions: Major Depressive Disorder;   Antidepressive Agents;   Pharmacogenetics;   Venlafaxine;   Fluoxetine
Interventions: Drug: Venlafaxine;   Drug: Fluoxetine
Outcome Measures: Hamilton Depression Rating Scale (HDRS);   C-reactive Protein and IL-6;   fasting blood glucose, lipid profiles
12 Recruiting Developing Adaptive Treatment Strategies for Children and Adolescents With Obsessive-compulsive Disorder.
Condition: Obsessive-Compulsive Disorder
Interventions: Drug: fluoxetine;   Behavioral: Group cognitive-behavioral therapy
Outcome Measures: Treatment response status at week 28;   Treatment response status at week 14;   Predictors of treatment response at week 28
13 Not yet recruiting RCT of a Neuroplasticity Agent and CI Therapy for Severe Arm Paresis After Stroke
Condition: Severe Stroke With Affected Arm Motor Function
Interventions: Drug: Fluoxetine;   Drug: Placebo;   Procedure: eCMIT;   Procedure: Usual Care
Outcome Measures: Grade 4/5 Motor Activity Log (MAL) Arm Use Scale;   Grade 4/5 MAL Arm Use scale;   Grade 4/5 Wolf Motor Function Test Performance Rate score
14 Recruiting A Positron Emission Topographic (PET) Study on Depression Patient With Electroacupuncture
Conditions: Major Depressive Disorder;   Depression
Interventions: Drug: Fluoxetine;   Procedure: DCEAS (Hwato®/ Dongbang®);   Procedure: n-CEA (Strietberger®)
Outcome Measures: HAMD-17;   SDS;   PET scanning;   Clinical response;   Remission;   Latency;   Adverse events
15 Recruiting Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation
Condition: Severe Mood Dysregulation
Interventions: Drug: lisdexamfetamine;   Drug: Placebo;   Drug: fluoxetine
Outcome Measures: Clinical Global Impression-Improvement-Severe Mood Dysregulation;   Pediatric Anxiety Rating Scale (PARS);   Children's Depression Rating Scale;   ADHD-IV Rating Scale;   ADHD IV Rating Scale;   Columbia Suicide Severity Scales;   Barnes Akathisia Scale;   Children's Affective Lability Scale;   Physical Symptom Checklist;   Revised Modified Overt Aggression Scale;   Screen for Children's Affective Reactivity;   Affective Reactivity Index
16 Recruiting Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients
Conditions: Obsessive-Compulsive Disorder;   Anxiety Disorders;   Mental Disorders
Interventions: Drug: Fluoxetine;   Drug: Sertraline;   Drug: Paroxetine;   Drug: Citalopram;   Drug: Fluvoxamine;   Behavioral: Exposure and Response Prevention
Outcome Measures: The change of Yale-Brown Obsessive-Compulsive Scale score;   The change of Beck Depression Inventory(BDI-II) score;   The change of Beck Anxiety Inventory(BAI) score;   The change of Stress Perceived Questionnaire (PSS-10) score;   The change of Behavioral Inhibition/Behavioral Activation System Scales score;   The change of Barratt Impulsiveness Scale 11 (BIS-11) score;   The change of Obsessive Beliefs Questionnaire-44(OBQ-44) score;   The NEO-Five Factor Inventory-Revised (NEO-FFI-R);   The Early Trauma Inventory Self Report-Short Form(ETISR-SF)
17 Recruiting Clinical Trial of Fluoxetine in Anxiety and Depression in Children, and Associated Brain Changes
Conditions: Depression;   Mood Disorder;   Anxiety Disorder;   Healthy
Intervention:
Outcome Measure:
18 Recruiting Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder
Conditions: Borderline Personality Disorder;   Suicide
Interventions: Drug: Fluoxetine;   Behavioral: DBT;   Drug: Citalopram
Outcome Measure: Suicidal and self-injurious behavior
19 Recruiting An Adaptive Treatment Strategy for Adolescent Depression-Continuation
Condition: Adolescent Depression
Interventions: Drug: Fluoxetine;   Behavioral: Interpersonal Psychotherapy
Outcome Measures: K-SADS-PL - baseline; change from baseline in KSADS at week 16 and 32;   BDI-II-baseline; change from baseline in BDI at weeks 4/8/12/16/24/32;   HRSD-baseline; change from baseline in HRSD at weeks 4/8/12/16/24/32;   CSSR-S-baseline; change from baseline in CSSR-S at weeks 4/8/12/16/24/32
20 Recruiting An Adaptive Treatment Strategy for Adolescent Depression
Condition: Adolescent Depression
Interventions: Drug: Fluoxetine;   Behavioral: Interpersonal Psychotherapy
Outcome Measures: K-SADS-PL - baseline; change from baseline in KSADS at week 16 and 32;   BDI-II-baseline; change from baseline in BDI at weeks 4/8/12/16/32;   HRSD-baseline; change from baseline in HRSD at weeks 4/8/12/16/32;   CSSR-S-baseline; change from baseline in CSSR-S at weeks 4/8/12/16/32